Novartis, Pfizer Advance Their NASH Ambitions Separately, As Partners
Executive Summary
Novartis thinks tropifexor may prove to be best-in-class FXR agonist, while Pfizer notes the complementary activity of its ACC and DGAT2 inhibitors. Their NASH trial collaboration is heading toward a Phase II launch in 2020.
You may also be interested in...
Novartis Sees Pliant’s NASH Program Offering Pathway To Treating Sickest Patients
Swiss pharma thinks targeted integrin inhibition could be part of the approach to treating cirrhotic NASH patients, those most at risk of needing a liver transplant.
Finland's Forendo Attracts Big Pharma For Liver Disease R&D
Turku, Finland-based Forendo Pharma has entered into a license and collaboration deal with Novartis involving the identification of novel drugs to treat chronic liver diseases.
Zydus Ready For Moraiya Reinspection In June
Zydus says its Moraiya plant should be ready for re-inspection at the end of June 2020, following a recent FDA warning letter. Meanwhile, as returns from levorphanol fall on the back of increased competition, the firm has written down investment by $37.5m causing Q2 profits to slump 74%. Post successful Phase II trials in the US for NASH and NAFLD indications, its hopes are now pinned on saroglitazar magnesium.
Need a specific report? 1000+ reports available
Buy Reports